MedKoo Cat#: 525665 | Name: MK-0557
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

MK-0557 is a highly selective, orally administered neuropeptide NPY5R antagonist, could limit weight regain after very-low-calorie diet (VLCD)-induced weight loss. Neuropeptide Y (NPY) is a potent orexigenic neuropeptide, and antagonism of NPY Y1 and NPY Y5 receptors (NPYxR) is considered a potentially important anti-obesity drug target.

Chemical Structure

MK-0557
MK-0557
CAS#328232-95-7

Theoretical Analysis

MedKoo Cat#: 525665

Name: MK-0557

CAS#: 328232-95-7

Chemical Formula: C22H19FN4O3

Exact Mass: 406.1441

Molecular Weight: 406.42

Elemental Analysis: C, 65.02; H, 4.71; F, 4.67; N, 13.79; O, 11.81

Price and Availability

Size Price Availability Quantity
100mg USD 1,450.00 2 weeks
200mg USD 2,150.00 2 weeks
500mg USD 2,950.00 2 weeks
1g USD 3,950.00 2 weeks
2g USD 6,950.00 2 weeks
5g USD 14,650.00 2 weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
935765-76-7 (alternate)
Synonym
MK0557; MK 0557; MK-0557
IUPAC/Chemical Name
(1s,4s)-N-(1-(2-fluorophenyl)-1H-pyrazol-3-yl)-1'-oxo-1'H-spiro[cyclohexane-1,3'-furo[3,4-c]pyridine]-4-carboxamide
InChi Key
RMYZIRFUCOMQRH-XLOAEROZSA-N
InChi Code
InChI=1S/C22H19FN4O3/c23-17-3-1-2-4-18(17)27-12-8-19(26-27)25-20(28)14-5-9-22(10-6-14)16-13-24-11-7-15(16)21(29)30-22/h1-4,7-8,11-14H,5-6,9-10H2,(H,25,26,28)/t14-,22+
SMILES Code
O=C([C@H]1CC[C@@](C2=C3C=CN=C2)(OC3=O)CC1)NC4=NN(C5=CC=CC=C5F)C=C4
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Biological target:
MK-0557 is a highly selective, orally available neuropeptide Y5 receptor antagonist with a Ki of 1.6 nM.
In vitro activity:
TBD
In vivo activity:
TBD
Solvent mg/mL mM comments
Solubility
DMF 5.0 12.30
DMF:PBS (pH 7.2) (1:1) 0.5 1.23
DMSO 101.5 249.91
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 406.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
TBD
In vitro protocol:
TBD
In vivo protocol:
TBD
1: Fichtner M, Lee E, Tomlinson E, Scott D, Cornelius P, Patterson TA, Carpino PA. Discovery and evaluation of spirocyclic derivatives as antagonists of the neuropeptide Y5 receptor. Bioorg Med Chem Lett. 2012 Apr 15;22(8):2738-43. doi: 10.1016/j.bmcl.2012.02.098. Epub 2012 Mar 6. PubMed PMID: 22445286. 2: MacNeil DJ. NPY Y1 and Y5 receptor selective antagonists as anti-obesity drugs. Curr Top Med Chem. 2007;7(17):1721-33. Review. PubMed PMID: 17979781. 3: Mifflin SW, Strack A. Obesity and the central nervous system. J Physiol. 2007 Sep 1;583(Pt 2):423. PubMed PMID: 17766646; PubMed Central PMCID: PMC2277037. 4: Erondu N, Addy C, Lu K, Mallick M, Musser B, Gantz I, Proietto J, Astrup A, Toubro S, Rissannen AM, Tonstad S, Haynes WG, Gottesdiener KM, Kaufman KD, Amatruda JM, Heymsfield SB. NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine. Obesity (Silver Spring). 2007 Aug;15(8):2027-42. PubMed PMID: 17712121. 5: Erondu N, Wadden T, Gantz I, Musser B, Nguyen AM, Bays H, Bray G, O'Neil PM, Basdevant A, Kaufman KD, Heymsfield SB, Amatruda JM. Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight loss. Obesity (Silver Spring). 2007 Apr;15(4):895-905. PubMed PMID: 17426325. 6: Erondu N, Gantz I, Musser B, Suryawanshi S, Mallick M, Addy C, Cote J, Bray G, Fujioka K, Bays H, Hollander P, Sanabria-Bohórquez SM, Eng W, Långström B, Hargreaves RJ, Burns HD, Kanatani A, Fukami T, MacNeil DJ, Gottesdiener KM, Amatruda JM, Kaufman KD, Heymsfield SB. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab. 2006 Oct;4(4):275-82. PubMed PMID: 17011500.